Misplaced Pages

Aubrey de Grey: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 18:36, 24 April 2005 edit207.179.104.160 (talk) →External links: interview with LiveScience← Previous edit Revision as of 00:02, 13 May 2005 edit undoNectarflowed (talk | contribs)5,007 edits copyedit. + quotes. + journal imageNext edit →
Line 3: Line 3:
'''Aubrey de Grey''' (b. ]) is a ], and is a Computer Associate at the Department of Genetics, ], ]. He is working to expedite the development of a 'cure' for human ]ular aging, a medical goal he refers to as ] (] means aging). To this end, he has identified what he concludes are the seven areas of the aging process that need to be addressed medically before this can be done. He has been interviewed in recent years in many news sources, including the ], the ], ], and ]. '''Aubrey de Grey''' (b. ]) is a ], and is a Computer Associate at the Department of Genetics, ], ]. He is working to expedite the development of a 'cure' for human ]ular aging, a medical goal he refers to as ] (] means aging). To this end, he has identified what he concludes are the seven areas of the aging process that need to be addressed medically before this can be done. He has been interviewed in recent years in many news sources, including the ], the ], ], and ].


Prior to his work as a ], de Grey was formally trained in ] and ]. He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today, and that the science is actually ahead of the funding. He works to identify and promote specific technological approaches to the reversal of various aspects of aging and for the more proactive and urgent approaches to extending the healthy human lifespan. Regarding this issue, De Grey is a supporter of ]. Prior to his work as a ], de Grey was formally trained in ] and ]. Regarding his background as a computer scientist, he states:
:"There are really very important differences between the type of creativity involved in being a basic scientist and being an engineer. It means that I’m able to think in very different ways and come up with approaches to things that are different from the way a basic scientist might think."
He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today, and that the science is actually ahead of the funding. He works to identify and promote specific technological approaches to the reversal of various aspects of aging, or as De Grey puts it, "the set of accumulated side effects from metabolism that eventually kills us,", and for the more proactive and urgent approaches to extending the healthy human lifespan. Regarding this issue, De Grey is a supporter of ].


journal. The journal's is claimed to include "world leaders in all relevant areas of biology and its social context, including stem cell therapy, tissue engineering, gene therapy, public policy, cancer therapies, demography and more".]]
], de Grey's current work at Cambridge centered around a detailed plan called ] (SENS) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the ], a contest designed to accelerate research into effective life extension interventions by awarding prizes to researchers who extend the lifespan of mice to unprecedented lengths. The prize reached $1 million USD in March 2005. De Grey believes that once this objective has been achieved in mice, a large amount of funding will be diverted to this kind of research, which would accelerate progress. ], de Grey's current work at Cambridge centered around a detailed plan called ] (SENS) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the ], a prize designed to accelerate research into effective life extension interventions by awarding monetary prizes to researchers who extend the lifespan of mice to unprecedented lengths. Regarding this, De Grey stated in March 2005 "if we are to bring about real regenerative therapies that will benefit not just future generations, but those of us who are alive today, we must encourage scientists to work on the problem of aging." The prize reached $1 million USD in March 2005. De Grey believes that once this objective has been achieved in mice, a large amount of funding will be diverted to this kind of research, which would accelerate progress.


Revision as of 00:02, 13 May 2005

File:De grey.jpg
Aubrey de Grey

Aubrey de Grey (b. 1963) is a biogerontologist, and is a Computer Associate at the Department of Genetics, University of Cambridge, England. He is working to expedite the development of a 'cure' for human cellular aging, a medical goal he refers to as engineered negligible senescence (senescence means aging). To this end, he has identified what he concludes are the seven areas of the aging process that need to be addressed medically before this can be done. He has been interviewed in recent years in many news sources, including the BBC, the New York Times, Fortune Magazine, and Popular Science.

Prior to his work as a biologist, de Grey was formally trained in computer science and bioinformatics. Regarding his background as a computer scientist, he states:

"There are really very important differences between the type of creativity involved in being a basic scientist and being an engineer. It means that I’m able to think in very different ways and come up with approaches to things that are different from the way a basic scientist might think."

He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today, and that the science is actually ahead of the funding. He works to identify and promote specific technological approaches to the reversal of various aspects of aging, or as De Grey puts it, "the set of accumulated side effects from metabolism that eventually kills us,", and for the more proactive and urgent approaches to extending the healthy human lifespan. Regarding this issue, De Grey is a supporter of life extension.

De Grey is Editor-in-Chief of the Rejuvenation Research journal. The journal's Editorial Board is claimed to include "world leaders in all relevant areas of biology and its social context, including stem cell therapy, tissue engineering, gene therapy, public policy, cancer therapies, demography and more".

As of 2005, de Grey's current work at Cambridge centered around a detailed plan called Strategies for Engineered Negligible Senescence (SENS) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the Methuselah Mouse Prize, a prize designed to accelerate research into effective life extension interventions by awarding monetary prizes to researchers who extend the lifespan of mice to unprecedented lengths. Regarding this, De Grey stated in March 2005 "if we are to bring about real regenerative therapies that will benefit not just future generations, but those of us who are alive today, we must encourage scientists to work on the problem of aging." The prize reached $1 million USD in March 2005. De Grey believes that once this objective has been achieved in mice, a large amount of funding will be diverted to this kind of research, which would accelerate progress.


External links

Category: